Angina Pectoris

Angina pectoris is a clinical syndrome of precordial discomfort or pressure due to transient myocardial ischemia without infarction. It is typically precipitated by exertion or psychologic stress and relieved by rest or sublingual nitroglycerin. Diagnosis is by symptoms, ECG, and myocardial imaging. Treatment may include aspirin, nitrates, β-blockers, Ca channel blockers, ACE inhibitors, statins, and coronary angioplasty or coronary artery bypass graft surgery.

Etiology

Angina pectoris occurs when cardiac workload and resultant myocardial O2 demand exceed the ability of coronary arteries to supply an adequate amount of oxygenated blood, as can occur when the arteries are narrowed. Narrowing usually results from atherosclerosis but may result from coronary artery spasm or, rarely, coronary artery embolism. Acute coronary thrombosis can cause angina if obstruction is partial or transient, but it usually causes MI.

Because myocardial O2 demand is determined mainly by heart rate, systolic wall tension, and contractility, narrowing of a coronary artery typically results in angina that occurs during exertion and is relieved by rest.

In addition to exertion, cardiac workload can be increased by disorders such as hypertension, aortic stenosis, aortic regurgitation, or hypertrophic cardiomyopathy. In such cases, angina can result whether atherosclerosis is present or not. These disorders can also decrease relative myocardial perfusion because myocardial mass is increased (causing decreased diastolic flow).

A decreased O2 supply, as in severe anemia or hypoxia, can precipitate or aggravate angina.

Pathophysiology

In stable angina, the relationship between workload or demand and ischemia is usually relatively predictable. However, atherosclerotic arterial narrowing is not entirely fixed; it varies with the normal fluctuations in arterial tone that occur in all people. Thus, more people have angina in the morning, when arterial tone is relatively high. Also, abnormal endothelial function may contribute to variations in arterial tone; eg, in endothelium damaged by atheromas, stress of a catecholamine surge causes vasoconstriction rather than dilation (normal response).

Symptoms and Signs

Angina may be a vague, barely troublesome ache or may rapidly become a severe, intense precordial crushing sensation. It is rarely described as pain. Discomfort is most commonly felt beneath the sternum, although location varies. Discomfort may radiate to the left shoulder and down the inside of the left arm, even to the fingers; straight through to the back; into the throat, jaws, and teeth; and, occasionally, down the inside of the right arm. It may also be felt in the upper abdomen. The discomfort of angina is never above the ears or below the umbilicus.

Some patients have atypical angina (eg, bloating, gas, abdominal distress), often ascribing symptoms to indigestion; belching may even seem to relieve the symptoms. Others have dyspnea due to the sharp, reversible increase in LV filling pressure that often accompanies ischemia. Frequently, the patient's description is imprecise, and whether the problem is angina, dyspnea, or both may be difficult to determine. Because ischemic symptoms require a minute or more to resolve, brief, fleeting sensations rarely represent angina.

Between and even during attacks of angina, physical findings may be normal. However, during the attack, heart rate may increase modestly, BP is often elevated, heart sounds become more distant, and the apical impulse is more diffuse. The 2nd heart sound may become paradoxical because LV ejection is more prolonged during an ischemic attack. A 4th heart sound is common, and a 3rd heart sound may develop. A mid or late systolic apical murmur, shrill—or blowing but not especially loud—may occur if ischemia causes localized papillary muscle dysfunction, causing mitral regurgitation.

Angina pectoris is typically triggered by exertion or strong emotion, usually persists no more than a few minutes, and subsides with rest. Response to exertion is usually predictable, but in some patients, exercise that is tolerated one day may precipitate angina the next because of variations in arterial tone. Symptoms are exaggerated when exertion follows a meal or occurs in cold weather; walking into the wind or first contact with cold air after leaving a warm room may precipitate an attack. Symptom severity is often classified by the degree of exertion resulting in angina (Table 1: Canadian Cardiovascular Society Classification System of Angina Pectoris).

Canadian Cardiovascular Society Classification System of Angina Pectoris

Class

Activities Triggering Chest Pain

1

Strenuous, rapid, or prolonged exertion

Not usual physical activities (eg, walking, climbing stairs)

2

Walking rapidly

Walking uphill

Climbing stairs rapidly

Walking or climbing stairs after meals

Cold

Wind

Emotional stress

3

Walking, even 1 or 2 blocks at usual pace and on level ground

Climbing stairs, even 1 flight

4

Any physical activity

Sometimes occurring at rest

Adapted from Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA Guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). Journal of American College of Cardiology 36:970–1062, 2000.

Canadian Cardiovascular Society Classification System of Angina Pectoris

Class

Activities Triggering Chest Pain

1

Strenuous, rapid, or prolonged exertion

Not usual physical activities (eg, walking, climbing stairs)

2

Walking rapidly

Walking uphill

Climbing stairs rapidly

Walking or climbing stairs after meals

Cold

Wind

Emotional stress

3

Walking, even 1 or 2 blocks at usual pace and on level ground

Climbing stairs, even 1 flight

4

Any physical activity

Sometimes occurring at rest

Adapted from Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA Guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). Journal of American College of Cardiology 36:970–1062, 2000.

Attacks may vary from several a day to symptom-free intervals of weeks, months, or years. They may increase in frequency (called crescendo angina) to a fatal outcome or gradually decrease or disappear if adequate collateral coronary circulation develops, if the ischemic area infarcts, or if heart failure or intermittent claudication supervenes and limits activity.

Nocturnal angina may occur if a dream causes striking changes in respiration, pulse rate, and BP. Nocturnal angina may also be a sign of recurrent LV failure, an equivalent of nocturnal dyspnea. The recumbent position increases venous return, stretching the myocardium and increasing wall stress, which increases O2 demand.

Angina may occur spontaneously during rest (called angina decubitus). It is usually accompanied by a modestly increased heart rate and a sometimes markedly higher BP, which increase O2 demand. These increases may be the cause of rest angina or the result of ischemia induced by plaque rupture and thrombus formation. If angina is not relieved, unmet myocardial O2 demand increases further, making MI more likely.

Unstable angina:

Because angina characteristics are usually predictable for a given patient, any changes (ie, rest angina, new-onset angina, increasing angina) should be considered serious, especially when the angina is severe (ie, Canadian Cardiovascular Society class 3). Such changes are termed unstable angina and require prompt evaluation and treatment.

Unstable angina is classified based on severity and clinical situation (Table 2: Braunwald Classification of Unstable Angina*). Also considered are whether unstable angina occurs during treatment for chronic stable angina and whether transient changes in ST-T waves occur during angina. If angina has occurred within 48 h and no contributory extracardiac condition is present, troponin levels may be measured to help estimate prognosis; troponin-negative indicates a better prognosis than troponin-positive.

Diagnosis

Diagnosis is suspected if chest discomfort is typical and is precipitated by exertion and relieved by rest. Presence of significant risk factors for coronary artery disease (CAD) in the history adds weight to reported symptoms. Patients whose chest discomfort lasts > 20 min or occurs during rest or who have syncope or heart failure are evaluated for an acute coronary syndrome (see Acute Coronary Syndromes (ACS)). Chest discomfort may also be caused by GI disorders (eg, reflux, esophageal spasm, indigestion, cholelithiasis), costochondritis, anxiety, panic attacks, hyperventilation, and other cardiac disorders (eg, pericarditis, mitral valve prolapse, supraventricular tachycardia, atrial fibrillation), even when coronary blood flow is not compromised (see Chest Pain).

ECG:

If typical exertional symptoms are present, ECG is indicated. Because angina resolves quickly with rest, ECG rarely can be done during an attack except during stress testing. If done during an attack, ECG is likely to show reversible ischemic changes: T wave discordant to the QRS vector, ST-segment depression (typically), ST-segment elevation, decreased R-wave height, intraventricular or bundle branch conduction disturbances, and arrhythmia (usually ventricular extrasystoles). Between attacks, the ECG (and usually LV function) at rest is normal in about 30% of patients with a typical history of angina pectoris, even those with extensive 3-vessel disease. In the remaining 70%, the ECG shows evidence of previous infarction, hypertrophy, or nonspecific ST-segment and T-wave (ST-T) abnormalities. An abnormal resting ECG alone does not establish or refute the diagnosis.

Stress testing:

More specific tests include stress testing with ECG or with myocardial imaging (eg, echocardiography, radionuclide imaging, MRI) and coronary angiography. Further testing is needed to confirm the diagnosis, evaluate disease severity, determine appropriate exercise levels for the patient, and help predict prognosis. If the clinical or working diagnosis is unstable angina, early stress testing is contraindicated.

Noninvasive tests are considered first. For CAD, the most accurate tests are stress echocardiography and myocardial perfusion imaging with single-photon emission CT (SPECT) or PET. However, these tests are more expensive than simple stress testing with ECG.

If a patient has a normal resting ECG and can exercise, exercise stress testing with ECG is done. In men with chest discomfort suggesting angina, stress ECG testing has a specificity of 70%; sensitivity is 90%. Sensitivity is similar in women, but specificity is lower, particularly in women < 55 (< 70%). However, women are more likely than men to have an abnormal resting ECG when CAD is present (32% vs 23%). Although sensitivity is reasonably high, exercise ECG can miss severe CAD (even left main or 3-vessel disease). In patients with atypical symptoms, a negative stress ECG usually rules out angina pectoris and CAD; a positive result may or may not represent coronary ischemia and indicates need for further testing.

When the resting ECG is abnormal, false-positive ST-segment shifts are common on the stress ECG, so patients should have stress testing with myocardial imaging. Exercise or pharmacologic stress (eg, with dobutamineSome Brand NamesNo US brand nameClick for Drug Monograph or dipyridamoleSome Brand NamesPERSANTINEClick for Drug Monograph infusion) may be used. The choice of imaging technique depends on institutional availability and expertise. Imaging tests can help assess LV function and response to stress; identify areas of ischemia, infarction, and viable tissue; and determine the site and extent of myocardium at risk. Stress echocardiography can also detect ischemia-induced mitral regurgitation.

Angiography:

Coronary angiography (see also Angiography) is the standard for diagnosing CAD but is not always necessary to confirm the diagnosis. It is indicated primarily to locate and assess severity of coronary artery lesions when revascularization (percutaneous intervention [PCI] or coronary artery bypass grafting [CABG]) is being considered. Angiography may also be indicated when knowledge of coronary anatomy is necessary to advise about work or lifestyle needs (eg, discontinuing job or sports activities). Although angiographic findings do not directly show hemodynamic significance of coronary lesions, obstruction is assumed to be physiologically significant when the luminal diameter is reduced > 70%. This reduction correlates well with the presence of angina pectoris unless spasm or thrombosis is superimposed.

Intravascular ultrasonography provides images of coronary artery structure. An ultrasound probe on the tip of a catheter is inserted in the coronary arteries during angiography. This test can provide more information about coronary anatomy than other tests; it is indicated when the nature of lesions is unclear or when apparent disease severity does not match symptom severity. Used with angioplasty, it can help ensure optimal placement of stents.

Guidewires with pressure or flow sensors can be used to estimate blood flow across stenoses. Blood flow is expressed as fractional flow reserve (FFR), which is the ratio of maximal flow through the stenotic area to normal maximal flow. These flow measurements are most useful when evaluating the need for angioplasty or CABG in patients with lesions of questionable severity (40 to 70% stenosis). An FFR of 1.0 is considered normal, while an FFR < 0.75 to 0.8 is associated with myocardial ischemia. Lesions with an FFR > 0.8 are less likely to benefit from stent placement.

Imaging:

Electron beam CT can detect the amount of Ca present in coronary artery plaque. The Ca score (from 1 to 100) is roughly proportional to the risk of subsequent coronary events. However, because Ca may be present in the absence of significant stenosis, the score does not correlate well with the need for angioplasty or CABG. Thus, the American Heart Association recommends that screening with electron beam CT should be done only for select groups of patients and is most valuable when combined with historical and clinical data to estimate risk of death or nonfatal MI. These groups may include asymptomatic patients with an intermediate Framingham 10-yr risk estimate of 10 to 20% and symptomatic patients with equivocal stress test results. It is particularly useful in ruling out significant CAD in patients presenting to the emergency department with atypical symptoms, normal troponin levels, and a low probability of hemodynamically significant coronary disease. These patients may have noninvasive testing as outpatients.

Clinical Calculator

Clinical Calculator

Multidetector row CT (MDRCT) coronary angiography can accurately identify coronary stenosis and has a number of advantages. The test is noninvasive, can exclude coronary stenosis with high accuracy, can establish stent or bypass graft patency, can visualize cardiac and coronary venous anatomy, and can assess calcified and noncalcified plaque burden. However, radiation exposure is significant, and the test is not suitable for patients with a heart rate of > 65 beats/min, those with irregular heart beats, and pregnant women. Patients must also be able to hold their breath for 15 to 20 sec, 3 to 4 times during the study.

Patients in whom invasive coronary angiography was unable to locate a major coronary artery or graft

Cardiac MRI has become invaluable in evaluating many cardiac and great vessel abnormalities. It may be used to evaluate CAD by several techniques, which enable direct visualization of coronary stenosis, assessment of flow in the coronary arteries, evaluation of myocardial perfusion and metabolism, evaluation of wall motion abnormalities during stress, and assessment of infarcted myocardium vs viable myocardium.

Current indications for cardiac MRI include evaluation of cardiac structure and function, assessment of myocardial viability, and possibly diagnosis and risk assessment of patients with either known or suspected CAD.

Prognosis

The main adverse outcomes are unstable angina, MI, and sudden death due to arrhythmias. Annual mortality rate is about 1.4% in patients with angina, no history of MI, a normal resting ECG, and normal BP. However, women with CAD tend to have a worse prognosis. Mortality rate is about 7.5% when systolic hypertension is present, 8.4% when the ECG is abnormal, and 12% when both are present. Type 2 diabetes about doubles the mortality rate for each scenario.

Prognosis worsens with increasing age, increasingly severe anginal symptoms, presence of anatomic lesions, and poor ventricular function. Lesions in the left main coronary artery or proximal left anterior descending artery indicate particularly high risk. Although prognosis correlates with number and severity of coronary arteries affected, prognosis is surprisingly good for patients with stable angina, even those with 3-vessel disease, if ventricular function is normal.

To prevent ischemia, all patients diagnosed with CAD or at high risk of developing CAD should take an antiplatelet drug daily. β-Blockers, unless contraindicated or not tolerated, are given to most patients. For some patients, prevention of symptoms requires Ca channel blockers or long-acting nitrates.

β-Blockers limit symptoms and prevent infarction and sudden death better than other drugs. β-Blockers block sympathetic stimulation of the heart and reduce systolic BP, heart rate, contractility, and cardiac output, thus decreasing myocardial O2 demand and increasing exercise tolerance. They also increase the threshold for ventricular fibrillation. Most patients tolerate these drugs well. Many β-blockers are available and effective. Dose is titrated upward as needed until limited by bradycardia or adverse effects. Patients who cannot tolerate β-blockers are given a Ca channel blocker with negative chronotropic effects (eg, diltiazemSome Brand NamesCARDIZEMCARTIA XTDILACOR XRClick for Drug Monograph, verapamilSome Brand NamesCALANClick for Drug Monograph). Those at risk of β-blocker intolerance (eg, those with asthma) may be tried on a cardioselective β-blocker (eg, bisoprololSome Brand NamesZEBETAClick for Drug Monograph) perhaps with pulmonary function testing before and after drug administration to detect drug-induced bronchospasm.

Nitroglycerin is a potent smooth-muscle relaxant and vasodilator. Its main sites of action are in the peripheral vascular tree, especially in the venous or capacitance system, and in coronary blood vessels. Even severely atherosclerotic vessels may dilate in areas without atheroma. NitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph lowers systolic BP and dilates systemic veins, thus reducing myocardial wall tension, a major determinant of myocardial O2 need. Sublingual nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph is given for an acute attack or for prevention before exertion. Dramatic relief usually occurs within 1.5 to 3 min, is complete by about 5 min, and lasts up to 30 min. The dose may be repeated every 4 to 5 min up to 3 times if relief is incomplete. Patients should always carry nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph tablets or aerosol spray to use promptly at the onset of an angina attack. Patients should store tablets in a tightly sealed, light-resistant glass container, so that potency is not lost. Because the drug deteriorates quickly, small amounts should be obtained frequently.

Long-acting nitrates (oral or transdermal) are used if symptoms persist after the β-blocker dose is maximized. If angina occurs at predictable times, a nitrate is given to cover those times. Oral nitrates include isosorbide dinitrateSome Brand NamesISORDILClick for Drug Monograph and mononitrate (the active metabolite of the dinitrate). They are effective within 1 to 2 h; their effect lasts 4 to 6 h. Sustained-release formulations of isosorbide mononitrateSome Brand NamesMONOKETClick for Drug Monograph appear to be effective throughout the day. For transdermal use, cutaneous nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph patches have largely replaced nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph ointments primarily because ointments are inconvenient and messy. Patches slowly release the drug for a prolonged effect; exercise capacity improves 4 h after patch application and wanes in 18 to 24 h. Nitrate tolerance may occur, especially when plasma concentrations are kept constant. Because MI risk is highest in early morning, an afternoon or early evening respite period from nitrates is reasonable unless a patient commonly has angina at that time. For nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph, an 8- to 10-h respite period seems sufficient. Isosorbide may require a 12-h respite period. If given once/day, sustained-release isosorbide mononitrateSome Brand NamesMONOKETClick for Drug Monograph does not appear to elicit tolerance.

Ca channel blockers may be used if symptoms persist despite use of nitrates or if nitrates are not tolerated. Ca channel blockers are particularly useful if hypertension or coronary spasm is also present. Different types of Ca channel blockers have different effects. Dihydropyridines (eg, nifedipineSome Brand NamesADALAT CCPROCARDIAClick for Drug Monograph, amlodipineSome Brand NamesNORVASCClick for Drug Monograph, felodipineSome Brand NamesPLENDILClick for Drug Monograph) have no chronotropic effects and vary substantially in their negative inotropic effects. Shorter-acting dihydropyridines may cause reflex tachycardia and are associated with increased mortality in CAD patients; they should not be used alone to treat stable angina. Longer-acting formulations of dihydropyridines have fewer tachycardic effects; they are most commonly used with a β-blocker. In this group, amlodipineSome Brand NamesNORVASCClick for Drug Monograph has the weakest negative inotropic effects; it may be used in patients with LV systolic dysfunction. DiltiazemSome Brand NamesCARDIZEMCARTIA XTDILACOR XRClick for Drug Monograph and verapamilSome Brand NamesCALANClick for Drug Monograph, other types of Ca channel blockers, have negative chronotropic and inotropic effects. They can be used alone in patients with β-blocker intolerance or asthma and normal LV systolic function but may increase cardiovascular mortality in patients with LV systolic dysfunction.

Almost all patients with STEMI as an alternative to unfractionated heparinSome Brand NamesPANHEPRINClick for Drug Monograph (unless PCI is indicated and can be done in < 90 min); drug continued until PCI or CABG is done or patient is discharged

For patients undergoing PCI, clopidogrelSome Brand NamesPLAVIXClick for Drug Monograph loading dose to be administered only in cardiac catheterization laboratory after angiography has confirmed that coronary anatomy is amenable to PCI (so as not to delay CABG if indicated)

Maintenance therapy required for at least 1 mo for bare-metal stents and for at least 12 mo for drug-eluting stents

1–3 boluses of 5 mg given 2–5 min apart as tolerated (up to 15 mg); then 25–50 mg po q 6 h, beginning 15 min after last IV dose and continued for 48 h; then 100 mg bid or 200 mg once/day given long term

Started at 5 mcg/min and increased 2.5–5.0 mcg every few minutes until required response occurs

Selected patients with ACS:

During the first 24 to 48 h, those with heart failure (unless hypotension is present), large anterior MI, persistent angina, or hypertension (BP is reduced by 10–20 mm Hg but not to < 80–90 mm Hg systolic)

For longer use, those with recurrent angina or persistent pulmonary congestion

Almost all patients with STEMI as an alternative to unfractionated heparinSome Brand NamesPANHEPRINClick for Drug Monograph (unless PCI is indicated and can be done in < 90 min); drug continued until PCI or CABG is done or patient is discharged

For patients undergoing PCI, clopidogrelSome Brand NamesPLAVIXClick for Drug Monograph loading dose to be administered only in cardiac catheterization laboratory after angiography has confirmed that coronary anatomy is amenable to PCI (so as not to delay CABG if indicated)

Maintenance therapy required for at least 1 mo for bare-metal stents and for at least 12 mo for drug-eluting stents

1–3 boluses of 5 mg given 2–5 min apart as tolerated (up to 15 mg); then 25–50 mg po q 6 h, beginning 15 min after last IV dose and continued for 48 h; then 100 mg bid or 200 mg once/day given long term

Started at 5 mcg/min and increased 2.5–5.0 mcg every few minutes until required response occurs

Selected patients with ACS:

During the first 24 to 48 h, those with heart failure (unless hypotension is present), large anterior MI, persistent angina, or hypertension (BP is reduced by 10–20 mm Hg but not to < 80–90 mm Hg systolic)

For longer use, those with recurrent angina or persistent pulmonary congestion

Revascularization:

Revascularization, either with PCI (eg, angioplasty, stenting) or CABG should be considered if angina persists despite drug therapy and worsens quality of life or if anatomic lesions (noted during angiography) put a patient at high risk of mortality. The choice between PCI and CABG depends on extent and location of anatomic lesions, the experience of the surgeon and medical center, and, to some extent, patient preference.

PCI is usually preferred for 1- or 2-vessel disease with suitable anatomic lesions and is increasingly being used for 3-vessel disease. Lesions that are long or near bifurcation points are often not amenable to PCI. However, as stent technology improves, PCI is being used for more complicated cases.

CABG improves survival for patients with left main disease, those with 3-vessel disease and poor LV function, and some patients with 2-vessel disease. However, for patients with mild or moderate angina (CCS class 1 or 2) or 3-vessel disease and good ventricular function, CABG appears to only marginally improve survival. For patients with 1-vessel disease, outcomes with drug therapy, PCI, and CABG are similar; exceptions are left main disease and proximal left anterior descending disease, for which revascularization appears advantageous.

Key Points

Angina pectoris occurs when cardiac workload exceeds the ability of coronary arteries to supply an adequate amount of oxygenated blood.

Symptoms of stable angina pectoris range from a vague, barely troublesome ache to a severe, intense precordial crushing sensation; they are typically precipitated by exertion, last no more than a few minutes, and subside with rest.

Do stress testing with ECG for patients with normal resting ECG or with myocardial imaging (eg, echocardiography, radionuclide imaging, MRI) for patients with abnormal resting ECG.

Do coronary angiography when revascularization (percutaneous intervention or coronary artery bypass grafting) is being considered.

Variant Angina

Most patients with variant angina have significant fixed proximal obstruction of at least one major coronary artery. Spasm usually occurs within 1 cm of the obstruction (often accompanied by ventricular arrhythmia).

Symptoms are anginal discomfort occurring mainly during rest, often at night, and only rarely and inconsistently during exertion (unless significant coronary artery obstruction is also present). Attacks tend to occur regularly at certain times of day.

Diagnosis is suspected if ST-segment elevation occurs during the attack. Between anginal attacks, the ECG may be normal or show a stable abnormal pattern. Confirmation is by provocative testing with ergonovineSome Brand NamesNo US brand nameClick for Drug Monograph or acetylcholine, which may precipitate coronary artery spasm, identified by significant ST-segment elevation or by observation of a reversible spasm during cardiac catheterization. Testing is done most commonly in a cardiac catheterization laboratory and occasionally in a coronary care unit.

Average survival at 5 yr is 89 to 97%, but mortality risk is greater for patients with both variant angina and atherosclerotic coronary artery obstruction. Usually, sublingual nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph promptly relieves variant angina. Ca channel blockers may effectively prevent symptoms. Theoretically, β-blockers may exacerbate spasm by allowing unopposed α-adrenergic vasoconstriction, but this effect has not been proved clinically. Oral drugs most commonly used are sustained-release diltiazemSome Brand NamesCARDIZEMCARTIA XTDILACOR XRClick for Drug Monograph 120 to 540 mg once/day, sustained-release verapamilSome Brand NamesCALANClick for Drug Monograph 120 to 480 mg once/day (dose must be reduced in patients with renal or hepatic dysfunction), or amlodipineSome Brand NamesNORVASCClick for Drug Monograph 15 to 20 mg once/day (dose must be reduced in elderly patients and patients with hepatic dysfunction). In refractory cases, amiodaroneSome Brand NamesCORDARONEClick for Drug Monograph may be useful. Although these drugs relieve symptoms, they do not appear to alter prognosis.

Syndrome X

Some patients with typical angina that is relieved by rest or nitroglycerinSome Brand NamesNITRO-DURClick for Drug Monograph have normal coronary arteriograms (eg, no atherosclerosis, embolism, or inducible arterial spasm). Some of these patients have ischemia detected during stress testing; others do not. In some patients, the cause of ischemia seems to be reflex intramyocardial coronary constriction and reduced coronary flow reserve. Other patients have microvascular dysfunction within the myocardium: The abnormal vessels do not dilate in response to exercise or other cardiovascular stressors; sensitivity to cardiac pain may also be increased. Prognosis is good, although symptoms of ischemia may recur for years. In many patients, β-blockers relieve symptoms. This disorder should not be confused with variant angina due to epicardial coronary spasm or with another disorder called syndrome X, which refers to the metabolic syndrome (see Metabolic Syndrome).

Silent Ischemia

Patients with CAD (particularly patients with diabetes) may have ischemia without symptoms. Ischemia is evidenced by transient asymptomatic ST-T abnormalities seen during 24-h Holter monitoring. Radionuclide studies can sometimes document asymptomatic myocardial ischemia during physical or mental stress (eg, mental arithmetic). Silent ischemia and angina pectoris may coexist, occurring at different times. Prognosis depends on severity of CAD.